Would you add immunotherapy to FOLFox if patient is not FLOT candidate for neoadjuvant gastric cancer extrapolating data from MATTERHON study?   

While it is always somewhat perilous to extrapolate from a proper study to lesser situations, this seems quite reasonable. It seems highly unlikely that the removal of taxotere from a fluoropyrimidine-oxaliplatin based regimen would render immunotherapy less effective in gastric cancer. In the MAT...